BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Su TH, Liu CJ, Tseng TC, Chou SW, Liu CH, Yang HC, Wu SJ, Chen PJ, Chen DS, Chen CL, Kao JH. Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study. Hepatology 2016;63:721-30. [PMID: 26662347 DOI: 10.1002/hep.28387] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Andrade XA, Paz LH, Nassar M, Oramas DM, Fuentes HE, Kovarik P, Mishra S, Singh A. Primary Liver Diffuse Large B-Cell Lymphoma following Complete Response for Hepatitis C Infection after Direct Antiviral Therapy. Acta Haematol 2018;139:77-80. [PMID: 29393087 DOI: 10.1159/000484653] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
2 Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. Journal of the Formosan Medical Association 2020;119:1019-40. [DOI: 10.1016/j.jfma.2020.04.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
3 Mihăilă RG. Hepatitis C virus - associated B cell non-Hodgkin's lymphoma. World J Gastroenterol 2016; 22(27): 6214-6223 [PMID: 27468211 DOI: 10.3748/wjg.v22.i27.6214] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
4 Petta S, Craxì A. Extrahepatic Manifestations of Chronic Viral C Hepatitis. Gastroenterol Clin North Am 2020;49:347-60. [PMID: 32389367 DOI: 10.1016/j.gtc.2020.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Aherfi S, Colson P, Audoly G, Nappez C, Xerri L, Valensi A, Million M, Lepidi H, Costello R, Raoult D. Marseillevirus in lymphoma: a giant in the lymph node. Lancet Infect Dis 2016;16:e225-34. [PMID: 27502174 DOI: 10.1016/S1473-3099(16)30051-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
6 Huang CF, Lai HC, Chen CY, Tseng KC, Kuo HT, Hung CH, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang JF, Dai CY, Chuang WL, Tsai PC, Peng CY, Yu ML. Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). Am J Gastroenterol 2020;115:1226-35. [PMID: 32221162 DOI: 10.14309/ajg.0000000000000606] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
7 Su T, Liu C, Tseng T, Chou S, Liu C, Yang H, Wu S, Chen P, Chen D, Chen C, Kao J. Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection. Aliment Pharmacol Ther 2019;49:331-9. [DOI: 10.1111/apt.15101] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 McLauchlan J, Innes H, Dillon JF, Foster G, Holtham E, McDonald S, Wilkes B, Hutchinson SJ, Irving WL; HCV Research UK Steering Committee. Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank. Int J Epidemiol 2017;46:1391-1391h. [PMID: 28338838 DOI: 10.1093/ije/dyw362] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
9 Innes H, McAuley A, Alavi M, Valerio H, Goldberg D, Hutchinson SJ. The contribution of health risk behaviors to excess mortality in American adults with chronic hepatitis C: A population cohort-study. Hepatology 2018;67:97-107. [PMID: 28777874 DOI: 10.1002/hep.29419] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
10 Su TH, Chen CL, Kao JH. Reply. Hepatology 2016;64:1814. [PMID: 27019093 DOI: 10.1002/hep.28578] [Reference Citation Analysis]
11 Huang SC, Kao JH. Strategies for hepatitis C virus treatment failure. J Formos Med Assoc 2021:S0929-6646(21)00426-5. [PMID: 34538553 DOI: 10.1016/j.jfma.2021.09.004] [Reference Citation Analysis]
12 Chen P, Yang H, Chou C, Chang L, Hsu M, Tsai T, Fang C, Su C, Lin Y, Feng Y, Chen C. The effectiveness and safety of sofosbuvir‐ledipasvir for patients with hepatitis C virus genotype 2 infection. Adv in Digestive Med. [DOI: 10.1002/aid2.13258] [Reference Citation Analysis]
13 Su TH, Yang HC, Tseng TC, Chou SW, Lin CH, Liu CH, Liu CJ, Chen CL, Kao JH. Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism. Mov Disord 2019;34:1882-90. [PMID: 31505068 DOI: 10.1002/mds.27848] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Carloni G, Fioretti D, Rinaldi M, Ponzetto A. Heterogeneity and coexistence of oncogenic mechanisms involved in HCV-associated B-cell lymphomas. Crit Rev Oncol Hematol 2019;138:156-71. [PMID: 31092372 DOI: 10.1016/j.critrevonc.2019.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Huang C, Yang Y, Chen Y, Chang J, Chen K, Lu C, Lee K, Chen P, Chen C. The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma. J Viral Hepat 2017;24:885-94. [DOI: 10.1111/jvh.12713] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
16 Lai YR, Chang YL, Lee CH, Tsai TH, Huang KH, Lee CY. Risk of Non-Hodgkin Lymphoma among Patients with Hepatitis B Virus and Hepatitis C Virus in Taiwan: A Nationwide Cohort Study. Cancers (Basel) 2022;14:583. [PMID: 35158850 DOI: 10.3390/cancers14030583] [Reference Citation Analysis]
17 Wyss K, Granath F, Wångdahl A, Djärv T, Fored M, Naucler P, Färnert A. Malaria and risk of lymphoid neoplasms and other cancer: a nationwide population-based cohort study. BMC Med 2020;18:296. [PMID: 33121475 DOI: 10.1186/s12916-020-01759-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Su T, Liu C, Tseng T, Chou S, Liu C, Yang H, Wu S, Chen P, Chen D, Chen C, Kao J. Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma. Aliment Pharmacol Ther 2019;49:589-98. [DOI: 10.1111/apt.15132] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
19 Wang SJ, Huang CF, Yu ML. Elbasvir and grazoprevir for the treatment of hepatitis C. Expert Rev Anti Infect Ther 2021;19:1071-81. [PMID: 33428488 DOI: 10.1080/14787210.2021.1874351] [Reference Citation Analysis]
20 Hussein O, El-Ghitany EM, Omran M, Matariek G, Elbadaly EA, Hamdy R, Gamal A, Zayed MM, Nasr A, Hamdy O, Elbasiony M, Abdelwahab K. High Seroprevalence of Hepatitis C Virus Antibody in Breast Cancer Patients in Egypt. Breast Cancer (Auckl) 2021;15:11782234211002499. [PMID: 33814915 DOI: 10.1177/11782234211002499] [Reference Citation Analysis]
21 Hsu SJ, Chiu MC, Fang YJ, Yang TH, Yu JJ, Chen CC, Kuo CC, Lee JY, Chen CH, Chen DS, Kao JH. Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C. J Formos Med Assoc 2019;118:1187-92. [PMID: 31279502 DOI: 10.1016/j.jfma.2019.06.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
22 Tovo PA, Garazzino S, Daprà V, Alliaudi C, Silvestro E, Calvi C, Montanari P, Galliano I, Bergallo M. Chronic HCV Infection Is Associated with Overexpression of Human Endogenous Retroviruses that Persists after Drug-Induced Viral Clearance. Int J Mol Sci 2020;21:E3980. [PMID: 32492928 DOI: 10.3390/ijms21113980] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Economides MP, Mahale P, Turturro F, Hosry J, Samaniego F, Granwehr BP, Torres HA. Development of non-Hodgkin lymphoma as a second primary cancer in hepatitis C virus-infected patients with a different primary malignancy. Leuk Lymphoma 2017;58:485-8. [PMID: 27348218 DOI: 10.1080/10428194.2016.1196817] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
24 Merli M, Carli G, Arcaini L, Visco C. Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma. World J Gastroenterol 2016; 22(38): 8447-8458 [PMID: 27784957 DOI: 10.3748/wjg.v22.i38.8447] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
25 Couronné L, Bachy E, Roulland S, Nadel B, Davi F, Armand M, Canioni D, Michot JM, Visco C, Arcaini L, Besson C, Hermine O. From hepatitis C virus infection to B-cell lymphoma. Ann Oncol 2018;29:92-100. [PMID: 29045541 DOI: 10.1093/annonc/mdx635] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
26 Chung H, Kim SY, Kim H. Clinical Research from a Health Insurance Database: Practice and Perspective. Korean J Med 2019;94:463-70. [DOI: 10.3904/kjm.2019.94.6.463] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
27 Su TH, Tseng TC, Liu CJ, Chou SW, Liu CH, Yang HC, Chen PJ, Chen DS, Chen CL, Kao JH. Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer. Int J Cancer 2020;147:901-8. [PMID: 31853972 DOI: 10.1002/ijc.32840] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Ponzetto A, Carloni G. Hepatitis C virus and lymphoma. Hepatology 2016;64:1813. [PMID: 27019322 DOI: 10.1002/hep.28580] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Lee MH, Huang CF, Lai HC, Lin CY, Dai CY, Liu CJ, Wang JH, Huang JF, Su WP, Yang HC, Kee KM, Yeh ML, Chuang PH, Hsu SJ, Huang CI, Kao JT, Chen CC, Chen SH, Jeng WJ, Yang HI, Yuan Y, Lu SN, Sheen IS, Liu CH, Peng CY, Kao JH, Yu ML, Chuang WL, Chen CJ. Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. Sci Rep. 2017;7:3718. [PMID: 28623331 DOI: 10.1038/s41598-017-02313-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
30 Chen CW, Cheng JS, Chen TD, Le PH, Ku HP, Chang ML. The irreversible HCV-associated risk of gastric cancer following interferon-based therapy: a joint study of hospital-based cases and nationwide population-based cohorts. Therap Adv Gastroenterol 2019;12:1756284819855732. [PMID: 31244896 DOI: 10.1177/1756284819855732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]